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Abstract
Background
Malaria control activities can have a disproportionately greater impact on Plasmodium fal-
ciparum than on P. vivax in areas where both species are coendemic. We investigated tem-
poral trends in malaria-related morbidity and mortality in Papua, Indonesia, before and after
introduction of a universal, artemisinin-based antimalarial treatment strategy for all Plasmo-
dium species.
Methods and findings
A prospective, district-wide malariometric surveillance system was established in April 2004
to record all cases of malaria at community clinics and the regional hospital and maintained
until December 2013. In March 2006, antimalarial treatment policy was changed to artemisi-
nin combination therapy for uncomplicated malaria and intravenous artesunate for severe
malaria due to any Plasmodium species. Over the study period, a total of 418,238 patients
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presented to the surveillance facilities with malaria. The proportion of patients with malaria
requiring admission to hospital fell from 26.9% (7,745/28,789) in the pre–policy change
period (April 2004 to March 2006) to 14.0% (4,786/34,117) in the late transition period (April
2008 to December 2009), a difference of −12.9% (95% confidence interval [CI] −13.5% to
−12.2%). There was a significant fall in the mortality of patients presenting to the hospital
with P. falciparum malaria (0.53% [100/18,965] versus 0.32% [57/17,691]; difference =
−0.21% [95% CI −0.34 to −0.07]) but not in patients with P. vivax malaria (0.28% [21/7,545]
versus 0.23% [28/12,397]; difference = −0.05% [95% CI −0.20 to 0.09]). Between the same
periods, the overall proportion of malaria due to P. vivax rose from 44.1% (30,444/69,098) to
53.3% (29,934/56,125) in the community clinics and from 32.4% (9,325/28,789) to 44.1%
(15,035/34,117) at the hospital. After controlling for population growth and changes in treat-
ment-seeking behaviour, the incidence of P. falciparum malaria fell from 511 to 249 per
1,000 person-years (py) (incidence rate ratio [IRR] = 0.49 [95% CI 0.48–0.49]), whereas the
incidence of P. vivax malaria fell from 331 to 239 per 1,000 py (IRR = 0.72 [95% CI 0.71–
0.73]). The main limitations of our study were possible confounding from changes in health-
care provision, a growing population, and significant shifts in treatment-seeking behaviour
following implementation of a new antimalarial policy.
Conclusions
In this area with high levels of antimalarial drug resistance, adoption of a universal policy of
efficacious artemisinin-based therapy for malaria infections due to any Plasmodium species
was associated with a significant reduction in total malaria-attributable morbidity and mortal-
ity. The burden of P. falciparum malaria was reduced to a greater extent than that of P. vivax
malaria. In coendemic regions, the timely elimination of malaria will require that safe and
effective radical cure of both the blood and liver stages of the parasite is widely available for
all patients at risk of malaria.
Author summary
Why was this study done?
• Multidrug-resistant malaria results in recurrent parasitaemia, a cumulative risk of anae-
mia, and progression to severe and fatal disease.
• Whilst artemisinin combination therapies (ACTs) and intravenous (IV) artesunate can
reduce morbidity and mortality associated with P. falciparum malaria, they have no
activity on the hypnozoite stages of P. vivax, which can relapse weeks to months follow-
ing an initial infection and sustain ongoing transmission of the parasite.
• In Papua, Indonesia, antimalarial resistance has emerged in both P. falciparum and P.
vivax. We used a prospective malariometric surveillance network to investigate the dif-
ferential impact of a universal policy of ACTs for uncomplicated malaria and IV artesu-
nate for severe malaria on the morbidity and mortality attributable to P. falciparum and
P. vivax.
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What did the researchers do and find?
• After controlling for population growth and changes in treatment-seeking behaviour,
the incidence of malaria after policy change fell by about 60% for P. falciparum and 40%
for P. vivax.
• There was a 50% fall in the proportion of patients with malaria requiring admission to
hospital and a 30% fall in malaria-related mortality. Bed occupancy due to admission
with malaria fell by 25%.
• Whilst there was a small decrease in the absolute incidence of P. vivax infections over
the 9-year study period, the proportion of malaria cases and malaria-attributable deaths
to P. vivax increased with time.
What do these findings mean?
• The results highlight the importance of highly effective blood schizontocidal antimalar-
ial drugs in reducing the overall burden of drug-resistant malaria.
• The rising proportion of malaria due to P. vivax emphasizes the need for safe and effec-
tive drug regimens that clear both the blood and liver stages of P. vivax in malaria elimi-
nation efforts in coendemic regions.
Introduction
Prompt and effective treatment of malaria reduces morbidity and limits onward transmission
of the Plasmodium parasite [1,2]. Large-scale use of highly efficacious antimalarial treatment
regimens has contributed to significant reductions in P. falciparum malaria in many malaria-
endemic regions [3,4]. P. vivax is more difficult to cure than P. falciparum because it forms
dormant liver stages (hypnozoites) that are intrinsically resistant to standard schizontocidal
drugs. Unless patients are treated with an effective drug regimen that clears both the blood and
liver stage of the parasite, these hypnozoites can reactivate periodically, causing recurrent
blood-stage infections (relapses) and ongoing transmission [5]. Malaria treatment campaigns
that do not include radically curative primaquine regimens for patients infected with P. vivax
may have only a modest effect on the number of cases of P. vivax malaria and thus are likely to
be associated with an increase in the proportion of malaria due to this parasite compared to P.
falciparum [6–8]. When primaquine radical cure is included in national guidelines, it is usually
prescribed without prior testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency.
To mitigate the risks of drug-induced haemolysis, many countries recommend a 15-mg daily
dose administered over 14 days despite evidence showing that 30 mg daily is more effective
[9]. When supervised, a 14-day regimen of primaquine can reduce the risk of P. vivax relapse
by more than 85% [10,11]; however, in most endemic settings, daily supervision of such a pro-
longed treatment regimen is not practical [12], and this can result in a significant reduction in
primaquine adherence and effectiveness [13–15]. In a large-scale observational study of
patients with vivax malaria in Papua, Indonesia, the effectiveness of unsupervised primaquine
was estimated to be only 10% [16].
Universal policy of artemisinin-based treatments for malaria
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Malaria endemicity in Papua, Indonesia, varies from hypo- to hyperendemic for P. falcipa-
rum and P. vivax [17]. In the early 2000s, clinical trials and ex vivo drug-susceptibility testing
demonstrated high-grade resistance to chloroquine and sulphadoxine + pyrimethamine in
endemic P. falciparum strains and chloroquine resistance in P. vivax strains [18–20]. Frequent,
recurrent parasitaemia is more likely in the setting of high-grade drug resistance and is associ-
ated with a cumulative risk of chronic anaemia, severe malaria, and mortality [21,22]. There-
fore, in March 2006, Indonesian national antimalarial treatment guidelines were changed to
an artemisinin combination therapy (ACT) (dihydroartemisinin plus piperaquine [DP]) for
uncomplicated malaria due to any Plasmodium species and intravenous (IV) artesunate for
severe malaria. At the same time, policy for the use of primaquine in patients with P. vivax
infections was changed from a total dose of 3.5 mg/kg over 14 days to a higher dose of 7 mg/kg
over 14 days. Information regarding the treatment changes was distributed widely via health
professionals and community leaders. In Mimika District, located in southern Papua Province,
hospital and community surveillance systems were put into place prior to the policy change to
allow an assessment of the subsequent changes in malaria-attributable morbidity and mortality
due to either P. falciparum or P. vivax. Previous analyses from the same location have quanti-
fied the burden of malaria in the hospital, the epidemiology of malaria in the community, and
local treatment-seeking behaviour [17,22,23]. The current analysis used routinely collected
surveillance data collected over a 9-year period (2004 to 2013) to investigate the temporal
trends in malaria morbidity and mortality before and after the change in antimalarial treat-
ment policy and the relative impact of this intervention on the burden of P. falciparum com-
pared with P. vivax.
Methods
Study site
The geography, climate, and demographics of Mimika District and its capital, Timika, have
been described previously [17,22]. Briefly, Mimika District lies in south central Papua, eastern
Indonesia, and covers an area of 21,522 km2; it has 12 subdistricts and 85 villages (Fig 1). The
region has fragmented forest ranging from extensive coastal lowlands to high mountainous
environments. Timika has a growing population of native Papuans and Indonesian migrants,
estimated to be 120,457 in 2004 and increasing to 196,401 in 2013 [24].
Malaria transmission is perennial with minimal seasonal variation and is normally
restricted to the lowland areas below 1,600-m elevation, where most of the population now
resides. There are three primary mosquito vectors: Anopheles koliensis, two members of the A.
farauti complex, and A. punctulatus; all of these vectors are both exo- and endophilic and are
primarily opportunistic in host-seeking behaviour. In 2005, the point prevalence of parasitae-
mia was estimated to be 16.3%: 46% due to P. falciparum, 39% due to P. vivax, and 11% due to
mixed P. falciparum/P. vivax infections [17]. Local P. vivax strains have a typical equatorial
relapse periodicity of 3–4 weeks [16,25].
Clinical trials conducted in Timika in 2004 and 2005 demonstrated failure of chloroquine
and sulphadoxine + pyrimethamine for the treatment of uncomplicated falciparum malaria
with a recurrence rate following combination treatment of 48% at day 28 [18]. Recurrence of
P. vivax at day 28 post chloroquine monotherapy was even higher at 65% [18]. Ex vivo studies
confirmed high-grade resistance to these drugs [19].
Health facilities
Formal healthcare facilities in the district include Rumah Sakit Mitra Masyarakat (RSMM), a
110-bed hospital funded by a local mining company providing healthcare free of charge to
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indigenous Papuan communities and at a nominal cost to non-Papuan Indonesians. Addition-
ally, there are 12 government-funded community primary health clinics (puskesmas) and 10
clinics administered by the local mining company. A government-funded hospital (Rumah
Sakit Umum Daerah [RSUD]) opened at the end of 2008 but did not begin seeing substantial
numbers of malaria patients until 2010. Antimalarial treatment can also be bought at a wide
range of regulated and unregulated private sector clinics and facilities in Timika [23].
Antimalarial treatment policy change
During the early 2000s, patients with uncomplicated malaria presenting to community clinics
were treated with chloroquine plus sulphadoxine + pyrimethamine if they had falciparum
malaria and with chloroquine plus low-dose primaquine (total dose 3.5 mg/kg) if they had
vivax malaria. At the RSMM hospital, patients with uncomplicated malaria were treated with
oral quinine, whereas patients with severe malaria received IV quinine. Those with P. vivax
malaria also received unsupervised low-dose primaquine [16]. In March 2006, the policy for
treatment of uncomplicated malaria due to any Plasmodium species at all public community
clinics and the hospital was changed to DP, a regimen with a risk of P. falciparum recrudes-
cence of 4.4% and P. vivax recurrence of 10% by day 42 [26]. At the same time, treatment of
Fig 1. Map of Mimika district in Papua Province, eastern Indonesia. Map adapted from WorldOfMaps (https://www.worldofmaps.com).
https://doi.org/10.1371/journal.pmed.1002815.g001
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severe malaria was changed from IV quinine to IV artesunate [27], and the dose of unsuper-
vised primaquine was doubled to 7 mg/kg divided over 14 days. The new unified antimalarial
treatment policy was adopted by RSUD hospital upon opening. Healthcare providers dissemi-
nated information regarding the antimalarial policy change and the benefits of DP to clinics
and to communities via village leaders.
Community surveillance
All patients presenting to one of the formal sector community (puskesmas) clinics with symp-
toms consistent with malaria had capillary blood collected for blood film examination or had a
rapid diagnostic test prior to antimalarial treatment. Between April 2004 and December 2009,
weekly reports on the number of blood film examinations and the number of patients treated
for malaria were collated by the district health authority. These reports were aggregated by the
species of infection within four age bands: <1 year, 1 to 5 years, 5 to 10 years, and those older.
Malariometric surveillance data were not collected from healthcare facilities in the private
sector.
Cluster-randomized, cross-sectional surveys to determine treatment-seeking behaviour
were conducted in 2005 and again in 2013, using an identical sampling strategy [17,23]. In
2005, during the pre–policy change period, 45.7% (349/764) of patients with malaria presented
to public sector facilities and would have been detected by the surveillance network, but in
2013, 6 years after policy change, this figure had risen to 67.3% (66/98; p< 0.001) [28]. The
shifts in treatment-seeking behaviour were apparent in all age groups. In the first household
survey, 32.3% (10/31) of members who died of any cause within the preceding year did so at
RSMM hospital compared to 26.3% (5/19) in 2013 (p = 0.656).
Hospital surveillance
All patient presentations to RSMM between 2004 and 2013 (whether to the outpatients depart-
ment, emergency department, or inpatient wards) were recorded by hospital administrators in
a QPro database. Patients were identified using a unique hospital reference number. Demo-
graphic data and the clinical diagnoses assigned by the attending physician were collected.
Drug prescriptions and results of full blood-count analyses from RSMM’s Coulter counter
were recorded in separate databases and identified by the same individual hospital reference
number. RSMM policy dictates that all outpatients with fever or other signs or symptoms con-
sistent with malaria and all inpatients regardless of presentation have a thick film prepared for
malaria microscopy. Thin films and rapid diagnostic tests were done after-hours when the lab-
oratory was closed. At RSUD hospital, a malaria register was initiated in January 2010, docu-
menting aggregated data on basic demographic details, infecting Plasmodium species,
fulfilment of clinical criteria for severe malaria, admission status, and malaria-related death in
patients at the hospital.
Entomology and meteorology
Since 2002, vector-control activities in the region have been provided predominantly by the
Public Health Malaria Control (PHMC) programme. These have included twice-yearly indoor
residual spraying (IRS) and distribution of long-lasting insecticide-treated bed nets (LLINs)
covering 10%–20% of households. Vector-control activities remained relatively constant from
2004 until mid-2013, when a large-scale IRS campaign and bed net distribution was
commenced.
PHMC maintained entomological surveillance at five routine ‘sentinel’ sites representative
of key locations in lowland Mimika from 1996 onwards. At each site, human-landing
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collections (HLCs) of mosquitoes were conducted at least once per week by 2 to 5 trained col-
lectors for 5 to 10 hours during evening hours. Captured mosquitoes were examined and iden-
tified by microscopy and their species recorded based on key morphological characters. Data
were combined to derive a human biting index over time. Automated daily rainfall was
recorded at Kuala Kencana township, representing one of the 12 subdistricts in Mimika. Rou-
tine entomology and meteorological data were available from January 2004 until June 2009.
Data preparation and statistical analysis
The analysis was conducted according to an a priori statistical plan (S1 Text) and is reported
according to RECORD (S1 RECORD Checklist). Additional multivariable regression analyses,
requested at statistical review, were also undertaken of key outcomes controlling for popula-
tion size, vector biting, and monthly time trends. Data from the hospitals, community clinics,
and meteorological and entomological surveillance were aggregated by calendar month. The
surveillance period was divided into four periods: pre–policy change (April 2004 to March
2006), early transition (April 2006 to March 2008, an equal interval to that observed before
policy change), late transition (April 2008 to December 2009, corresponding to the end of the
community and entomology surveillance), and post transition (January 2010 to December
2013, corresponding to the period between the opening of the new RSUD hospital and the end
of the study period) (S1 Fig, S1 Table).
Estimated malaria incidence rates were derived for the pre-policy and the early and late transi-
tion periods using absolute numbers of malaria cases from both the hospital and community sur-
veillance, the estimated population at the time (assuming linear growth between the censuses),
and estimates of the proportion of febrile patients seeking treatment within the malariometric
surveillance system, obtained from the two household surveys in 2005 and 2013 (S1 Fig). In a sen-
sitivity analysis, the incidence of malaria was also derived assuming no change in treatment-seek-
ing behaviour. Analyses of malaria-related morbidity and mortality were limited to RSMM data,
as the necessary information was not collected from the other sites. To account for monthly time
trends, vector biting, and population growth, Poisson regression analyses of the data pre-2009
were performed to estimate the adjusted incidence rate ratios (IRRs) for falciparum and for vivax
malaria for the late transition period versus the pre–policy change period. Similar analyses were
undertaken for hospital admissions using binomial regression to estimate the risk ratio.
All graphing and statistical analysis was done in STATA version 15.1 (StataCorp, College
Station, TX, United States). Temporal trends in outcomes were presented graphically over the
entire study period. Comparisons of outcomes before and after policy change were made using
medians (with interquartile ranges [IQRs]), proportions (n/N with absolute differences and
binomial 95% confidence intervals [CIs]), incidence rates (per 1,000 person-years [py] with
IRRs and Poisson 95% CIs). Comparisons of prospectively collected community and hospital
surveillance data were restricted to the pre-policy and late transition periods to ensure inclu-
sion of the community surveillance (which ended in December 2009) and to avoid bias associ-
ated with the opening of RSUD (which began admitting significant numbers of malaria
patients in January 2010). p-Values were not presented, since numbers of cases from the com-
munity clinics and hospitals were large and statistical significance was achieved even in the
absence of clinical significance.
Ethical approval
Ethical approval for this study was obtained from the Health Research Ethics Committees of
the University of Gadjah Mada, Indonesia (KE/FK/544/EC), and Menzies School of Health
Research, Darwin, Australia (HREC 10.1397).
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Results
Rainfall and entomology
Between April 2004 and June 2009, the mean daily rainfall was 27.8 mm with small peaks in
mid-2005, mid-2007, and mid-2008 (Fig 2, S1 Data). Over the same period, 204,968 human-
hours of nighttime mosquito collections were conducted; the estimated mean number of
anopheline bites per py was 145 (range 28 to 534) (Fig 2, S1 Data). There was a large peak in
the number of mosquitoes caught throughout much of 2007; the mean estimated number of
bites per py during this period was 238 (range 34 to 534). Overall, A. koliensis accounted for
85.0% (6,992/8,222) of mosquitoes captured by HLC, compared to 11.6% (956/8,222) for A.
farauti species complex and 3.3% (274/8,222) for A. punctulatus.
Community facilities
Data were gathered from 12 community outpatient facilities over a period of 69 months (April
2004 to December 2009). A total of 671,386 blood films were examined, of which 193,566
(28.8%) were positive for malaria; 98,530 (50.9%) were due to P. falciparum, 87,632 (45.3%)
were due to P. vivax, 3,308 (1.7%) were due to P. malariae, and 4,096 (2.1%) were mixed spe-
cies infections (Table 1). Slide positivity for P. falciparum declined from 14.8% (37,304/
251,286) before treatment policy change to 13.0% (25,362/194,792) in the late transition
period, a difference of −1.8% (95% CI −2.0% to −1.6%). Over the same period, the slide positiv-
ity for P. vivax increased from 11.5% (28,872/251,286) to 14.8% (28,861/194,792), differ-
ence = 3.3% (95% CI 3.1%–3.5%). The corresponding proportion of malaria infections due to
P. vivax rose from 44.1% (30,444/69,098) to 53.3% (29,934/56,125), difference = 9.2% (95% CI
8.7%–9.8%) (Fig 3, S2 Data). In multivariable analyses controlling for population size, vector
biting, and monthly time trends, the IRR for the late transition period compared with the pre–
policy change period was 0.70 (95% CI 0.67–0.74) for falciparum malaria and 1.02 (95% CI
0.97–1.07) for vivax malaria.
The proportion of all blood films read that were positive for P. falciparum gametocytes fell
steadily over the study period from 1.4% (3,491/251,286) pre–policy change to 0.7% (1,419/
194,792) in the late transition period, a difference of −0.7% (95% CI −0.7% to −0.6%) (Fig 3).
Over the same time interval, there was an increase in the overall gametocyte slide positivity for
P. vivax, which rose from 1.9% (4,700/251,286) to 2.3% (4,403/194,792), a difference of 0.4%
(95% CI 0.3%–0.5%).
RSMM hospital data
Data from RSMM were available for 117 months (April 2004 to December 2013). Overall,
there were 1,054,674 patient presentations to the hospital, of which 196,380 (18.6%) were asso-
ciated with malaria, 100,078 (51.0%) with P. falciparum, 65,306 (33.3%) with P. vivax, 5,097
(2.6%) with P. malariae, 120 (0.06%) with P. ovale, and 25,779 (13.1%) with mixed species
infections. In total, 27,890 (14.2%) of the patients with malaria required admission to hospital,
and 595 (0.3%) died in hospital. In the posttransition period, 22.5% (27,480/122,232) of
malaria diagnosed at a tertiary facility was at the newly opened RSUD hospital (S3 Data);
therefore, before-and-after comparisons at the RSMM hospital were only made between the
pre–policy change era and the late transition period.
Before policy change, the most commonly prescribed blood schizontocide at RSMM hospi-
tal was oral quinine (20,364/24,538; 83.0%) (Fig 4); thereafter, DP was prescribed in 88.6%
(139,002/156,902) and artesunate-amodiaquine in 6.0% (9,442/156,902) of malaria cases.
Patients requiring IV therapy were prescribed quinine in 83.1% (3,858/4,641) of cases before
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policy change, but thereafter, 98.5% (16,414/16,661) were treated with IV artesunate. Before
policy change, 63.5% (4,455/7,019) of patients with P. vivax malaria were treated with a 14-day
primaquine regimen, and after policy change, this rose to 71.1% (51,344/72,196).
The proportion of all presentations to RSMM that were related to malaria rose from 16.5%
(28,789/174,289) before policy change to 18.3% (34,117/186,312) in the late transition period
(difference of 1.8% [95% CI 1.5%–2.0%]) (Fig 5). This was driven by a rise in the proportion of
outpatients with malaria, which increased from 13.6% (21,044/155,029) to 17.3% (29,331/
169,391), a difference of 3.7% (95% CI 3.5%–4.0%). Over the same period, the proportion of
inpatients with malaria fell from 40.2% (7,745/19,260) to 28.3% (4,786/16,921; difference of
−11.9% [95% CI −12.9% to −11.0%]), and the proportion of patients with malaria requiring
admission fell from 26.9% (7,745/28,789) to 14.0% (4,786/34,117; difference of −12.9% [95%
CI −13.5% to −12.2%]) (Fig 6, Table 1 and S3 Data). In multivariable analyses comparing the
pre–policy change and late transition period, after controlling for monthly trends, the propor-
tion of inpatients with malaria decreased by 0.56-fold (95% CI 0.51–0.60), and the proportion
of patients with malaria requiring admission fell by 0.82-fold (95% CI 0.75–0.90).
Of the patients admitted with malaria, the median length of stay decreased from 3 days
(IQR 2–4) to 2 days (IQR 2–4), and this was associated with a fall in the median total monthly
Fig 2. Community entomological and meteorological surveillance. Predicted number of Anopheles (‘An’) mosquito bites per year by month for the three
main Plasmodium vectors in Mimika District (top) and mean daily rainfall by month (bottom).
https://doi.org/10.1371/journal.pmed.1002815.g002
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inpatient bed occupancy due to malaria from 1,033.5 days (IQR 897–1,251.5) pre–policy
change to 769.5 days (IQR 685.5–856) post policy change (Fig 6). Overall, the proportion of
malaria cases due to P. vivax mono- or mixed species infection rose from 32.4% (9,325/28,789)
to 44.1% (15,035/34,117), a difference of 11.7% (95% CI 10.9%–12.4%) (Fig 7). Malaria due to
any Plasmodium species collectively accounted for 57.7% (4,388/7,603) of all severe anaemia at
the hospital before policy change and 41.7% (1,928/4,627) in the late transition period, a differ-
ence of −16.0% (95% CI −17.8% to −14.2%) (Fig 7).
Malaria-attributable mortality
Before policy change, malaria accounted for 15.5% (137/886) of all deaths at RSMM, with
0.48% (137/28,789) of patients who presented with malaria dying during their hospital
encounter. In the late transition period, the corresponding figures were 10.4% (100/961; differ-
ence = −5.1% [95% CI −8.1 to −2.0]) and 0.29% (100/34,117; difference = −0.18% [95% CI
−0.28 to −0.08]) (Fig 6, S3 Data). Over the same period, there was a significant fall in the mor-
tality attributable to P. falciparum (0.53% [100/18,965] versus 0.32% [57/17,691]; difference =
−0.21% [95% CI −0.34 to −0.07]), but this was not apparent for P. vivax (0.28% [21/7,545] ver-
sus 0.23% [28/12,397]; difference = −0.05% [95% CI −0.20 to 0.09]) or nonmalarial disease
Table 1. Patients presenting and diagnosed with malaria at community clinics and the RSMM hospital.
Pre–Policy Change Period Early Transition Period Late Transition Period Posttransition Period Total
Apr 2004–Mar 2006 Apr 2006–Mar 2008 Apr 2008–Dec 2009 Jan 2010–Dec 2013
Community Surveillance
Total slide examinations 251,286 225,308 194,792 - 671,386
P. falciparum 37,304 (14.8%) 35,864 (15.9%) 25,362 (13.0%) - 98,530
P. vivax 28,872 (11.5%) 29,899 (13.3%) 28,861 (14.8%) - 87,632
P. malariae 1,350 (0.5%) 1,129 (0.5%) 829 (0.4%) - 3,308
Mixed species 1,572 (0.6%) 1,451 (0.6%) 1,073 (0.6%) - 4,096
Total malaria cases 69,098 (27.5%) 68,343 (30.3%) 56,125 (28.8%) - 193,566
P. falciparum gametocytes 3,491 (1.4%) 2,636 (1.2%) 1,419 (0.7%) - 7,546
P. vivax gametocytes 4,700 (1.9%) 4,192 (1.9%) 4,403 (2.3%) - 13,295
Outpatient presentations to the RSMM Hospital
Total outpatient presentations 155,029 181,493 169,391 453,506 959,419
P. falciparum 13,654 (8.8%) 18,977 (10.5%) 14,801 (8.7%) 35,259 (7.8%) 82,691
P. vivax 6,056 (3.9%) 9,472 (5.2%) 11,198 (6.6%) 32,464 (7.2%) 59,190
P. malariae 411 (0.3%) 871 (0.5%) 1,230 (0.7%) 2,153 (0.5%) 4,665
P. ovale 17 (0.01%) 25 (0.01%) 36 (0.02%) 32 (0.01%) 110
Mixed species 906 (0.6%) 2,248 (1.2%) 2,066 (1.2%) 16,614 (3.7%) 21,834
All malaria 21,044 (13.6%) 31,593 (17.4%) 29,331 (17.3%) 86,522 (19.1%) 168,490
Hospital admissions at the RSMM Hospital
Total hospital admissions 19,260 20,293 16,921 38,781 95,255
P. falciparum 5,311 (27.6%) 4,863 (24%) 2,890 (17.1%) 4,323 (11.1%) 17,387
P. vivax 1,489 (7.7%) 1,383 (6.8%) 1,199 (7.1%) 2,045 (5.3%) 6,116
P. malariae 70 (0.4%) 105 (0.5%) 122 (0.7%) 135 (0.3%) 432
P. ovale 1 3 3 3 10
Mixed species 874 (4.5%) 720 (3.5%) 572 (3.4%) 1,779 (4.6%) 3,945
All malaria 7,745 (40.2%) 7,074 (34.9%) 4,786 (28.3%) 8,285 (21.4%) 27,890
Abbreviation: RSMM, Rumah Sakit Mitra Masyarakat.
https://doi.org/10.1371/journal.pmed.1002815.t001
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(0.51% [749/145,500] versus 0.57% [861/152,195], difference = 0.05% [95% CI −0.002 to
0.10]). Overall, P. vivax accounted for 15.3% (21/137) of malaria-related deaths pre–policy
change and 28.0% (28/100) in the late transition period, a difference of 12.7% (95% CI 2.0%–
23.3%) (S3 Data).
Assuming that 30% of deaths in the region occurred at RSMM hospital, the overall malaria-
attributable mortality rate in the population of Mimika District fell from 1.90 (95% CI 1.73–
2.08) per thousand py before the policy change to 1.29 (95% CI 1.15–1.43) per 1,000 py in the
late transition period, a rate difference of −0.61 (95% CI −0.83 to −0.39) per 1,000 py.
Combined estimates of malaria incidence
When community and hospital surveillance data were combined, a total of 295,971 cases of
malaria were diagnosed between April 2004 and December 2009. The overall incidence of
malaria was 406 (95% CI 404–409) per 1,000 py before policy change, 372 (95% CI 370–374)
per 1,000 py in the early transition period, and 351 (95% CI 349–354) per 1,000 py in the late
transition period (Table 2, S4 Data). Assuming that 45.7% of patients with malaria were
detected by the surveillance network pre–policy change and 67.3% in the late and posttransi-
tion periods, the overall incidence of P. falciparum fell from 511 to 249 per 1,000 py (IRR =
0.49 [95% CI 0.48–0.49]), whereas the incidence of P. vivax fell from 331 to 239 per 1,000 py
(IRR = 0.72 [95% CI 0.71–0.73]). In a sensitivity analysis assuming no shift in treatment-seek-
ing behaviour, the incidence of P. falciparum fell from 234 to 168 per 1,000 py (IRR = 0.72
[95% CI 0.71–0.73]), whereas the incidence of P. vivax rose from 152 to 161 per 1,000 py
(IRR = 1.06 [95% CI 1.05–1.08]).
Fig 3. Malaria surveillance gathered from community healthcare facilities. Absolute number (‘N.’) of malaria cases
detected within the community surveillance network by Plasmodium species and month (top) and proportion of all
blood films examined in the community with gametocytes (‘gams’) by Plasmodium species and time (bottom).
https://doi.org/10.1371/journal.pmed.1002815.g003
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Fig 4. Antimalarial drug prescriptions at Mitra Masyarakat hospital. Number of oral blood schizontocidal drug prescriptions (top), PQ prescriptions
(middle), and IV blood schizontocidal drug prescriptions (bottom) at Mitra Masyarakat Hospital by month. Low-dose PQ is defined as a total dose of�1.5 to
<5 mg/kg. High-dose PQ is defined as a total dose of�5 mg/kg. IV, intravenous; PQ, primaquine.
https://doi.org/10.1371/journal.pmed.1002815.g004
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Fig 5. Malaria cases at Mitra Masyarakat hospital. Number of outpatient (top) and inpatient (middle) malaria cases at Mitra Masyarakat Hospital by
Plasmodium species and month and proportion of all hospital malaria cases due to the different Plasmodium species (bottom).
https://doi.org/10.1371/journal.pmed.1002815.g005
Universal policy of artemisinin-based treatments for malaria
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002815 May 29, 2019 13 / 23
Fig 6. Malaria-related morbidity and mortality at Mitra Masyarakat hospital. Proportion of all patients presenting to Mitra Masyarakat Hospital who were
admitted by Plasmodium species and month (top). Total number of days of inpatient bed occupancy × 100/month by Plasmodium species (second from top).
Proportion of all patients presenting to Mitra Masyarakat Hospital who were anaemic (Hb< 7 g/dL) (third from top) and who died (bottom) by Plasmodium
species and month. Hb, haemoglobin.
https://doi.org/10.1371/journal.pmed.1002815.g006
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Fig 7. Proportion of malaria morbidity and mortality attributable to Pv mono- or mixed infection. In the community and hospital (top). In the
hospital stratified by age group (middle). In the hospital: malaria-related hospital admissions, inpatient bed days, malaria-related anaemia, and malaria-
related deaths (bottom). Pv, P. vivax.
https://doi.org/10.1371/journal.pmed.1002815.g007
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Discussion
In March 2006, Indonesia was the first malaria-endemic country to adopt a unified schizonto-
cidal treatment policy for malaria due to any Plasmodium species: DP for uncomplicated
malaria and IV artesunate for severe malaria. These changes came on a background of failing
treatment regimens due to high-grade multidrug resistance in both P. falciparum and P. vivax
species. In Mimika District, southern Papua, the uptake of the new policy was rapid, with the
new treatment regimens adopted into practice in most public health facilities within a month.
In this high-transmission setting, we found that the implementation of highly effective antima-
larial treatment regimens was associated with a marked reduction in both malaria-related mor-
bidity and mortality. The incidence of malaria and the proportion of malaria requiring
admission to hospital fell by one-half, bed occupancy of patients with malaria fell by 26%, and
malaria-related mortality fell by one-third. Associated with these changes, the proportion of
patients with malaria attributable to P. vivax increased from 41% to 54%, and the proportion
of malaria-related deaths attributable to P. vivax rose from 15% to 28%.
Table 2. Total number of community and hospital malaria cases and incidence of malaria before and after policy change.
Pre–Policy Change
Period
Early Transition
Period
Late Transition
Period
Posttransition Period
Apr 2004–Mar 2006 Apr 2006–Mar 2008 Apr 2008–Dec 2009 Jan 2010–Dec 2013
Population of Mimikaa 120,457 143,723 148,124 189,447
Months of observation 24 24 21 48
Person-years of observation 240,914 287,446 259,217 757,788
Percent of patients with malaria attending the surveillance
networkb
45.7% - - 67.3%
Number of malaria cases
P. falciparum 56,269 59,704 43,464 53,749c
P. vivax 36,417 40,754 41,659 46,491c
P. malariae 1,831 2,105 2,193 2,477c
Mixed species 3,352 4,419 3,719 19,515c
Overalld 97,887 107,010 91,074 122,267c
Incidence rate of malaria (per 1,000 person-years) assuming complete ascertainment of all malaria patients (95% confidence interval)
P. falciparum 234 (232–236) 208 (206–209) 168 (166–169) -
P. vivax 152 (150–153) 142 (140–143) 161 (159–162) -
P. malariae 7.6 (7.3–8.0) 7.3 (7.0–7.6) 8.5 (8.1–8.8) -
Mixed species 13.9 (13.4–14.4) 15.4 (14.9–15.8) 14.3 (13.9–14.8) -
Overall 406 (404–409) 372 (370–375) 351 (349–354) -
Incidence rate of malaria (per 1,000 person-years) assuming shifts in treatment-seeking behaviour (95% confidence interval)
P. falciparum 511 (508–514) - 249 (247–251) -
P. vivax 331 (328–333) - 239 (237–241) -
P. malariae 16.6 (16.1–17.2) - 12.6 (12.1–13.0) -
Mixed species 30.4 (29.8–31.2) - 21.3 (20.8–21.9) -
Overall 889 (885–893) - 522 (519–525) -
aPopulation estimates taken at midpoint of the time interval.
bEstimates for the proportion of patients with malaria attending the public provider and thus who will have been detected by the surveillance network were derived from
household surveys conducted in 2005 and 2013, reported previously [28].
cIncludes patients attending the new RSUD hospital but excludes community cases due to surveillance finishing in December 2009.
dIncludes 120 cases of P. ovale.
Abbreviation: RSUD, Rumah Sakit Umum Daerah.
https://doi.org/10.1371/journal.pmed.1002815.t002
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Our study highlights the complexity of defining temporal changes in the burden of malaria
at a population level over a long period of time [1,2,29]. During the 9 years of surveillance,
there was a substantial increase in the local population, fluctuations in rainfall and vector mos-
quito numbers, and marked changes in healthcare provision and treatment-seeking behaviour.
Our comprehensive surveillance quantified patient numbers at the only lowland hospital
(until late 2009) and all public and mine-supported clinics, which collectively diagnosed and
treated almost half a million cases of malaria over the study period. Although these clinics
offered healthcare for free or at a nominal cost, our treatment-seeking surveys suggested that
initially only 46% of patients with malaria sought treatment in the public sector. However, fol-
lowing the change in policy, there was a significant shift in behaviour, with 67% of patients
seeking treatment in the public sector where they could access DP, a drug perceived to be
highly effective compared to previously available treatments [28]. This shift in behaviour,
along with the rise in the total population and an increase in vector numbers in 2007 (Fig 2),
may have contributed to the initial surge in malaria cases and slide positivity observed in the
community and hospital outpatients department in the early transition period but a subse-
quent fall in these metrics in the late transition period as the impact of ACT on P. falciparum
began to manifest (Fig 3). Conversely, in the latter part of the study, a new public hospital facil-
ity (RSUD) outside of the initial surveillance network was opened and assumed care of approx-
imately 20% of malaria inpatients, acting to artificially decrease the burden of malaria at
RSMM hospital. To control for these confounding factors, the overall temporal trends by
month are presented, but the comparisons pre–and post–policy change were restricted conser-
vatively to the period immediately before policy change and the late transition period, prior to
the opening of the new hospital facility.
The replacement of failing treatment regimens with highly efficacious schizontocidal treat-
ment has potential to reduce malaria-related morbidity and mortality and decrease the risk of
recurrent parasitaemia and ongoing transmission [30]. In Papua in 2005, the efficacy of DP
against P. falciparum and P. vivax was greater than 95%, with antimalarial efficacy sustained
against both species throughout the study period [26,31]. In the same year, a clinical trial of
patients with severe malaria at the RSMM hospital demonstrated that IV artesunate reduced
associated mortality by 35% compared to IV quinine [27]. Our analysis highlights that, follow-
ing implementation of both of these artemisinin-based treatment strategies in April 2006,
there was a significant reduction in malaria-related morbidity and mortality, which was most
apparent at the RSMM hospital. Whilst outpatient numbers actually increased over the study
period, both the absolute number of malaria admissions and the proportion of malaria patients
requiring admission fell (the latter from 27% to 14%). This was associated with a marked
reduction in total bed occupancy due to malaria, shorter admission times, and a lower risk of
severe anaemia- and malaria-related mortality. In total, 264 bed days per month were made
available at the hospital for the treatment of other diseases. These findings are consistent with
African studies that have shown that the most prominent impact of enhanced malaria control
activities is a reduction in severe malaria and mortality [32,33]. The variation in malaria mor-
bidity was less marked in the community, where absolute numbers of patients remained high
and where there was only a modest fall in malaria prevalence from 16.3% to 12.2%. However,
after accounting for population growth and shifts in treatment-seeking behaviour, the esti-
mated overall incidence of malaria in the community also fell significantly.
A consistent finding in both the hospital and community setting was the marked increase
in the proportion of malaria caused by P. vivax. Policy change was associated with a differential
variation between species in the overall cases of malaria, severe disease, and gametocyte car-
riage. At the start of the study, P. vivax accounted for 32% of all malaria at the hospital and
44% in the community. By the late transition period, P. vivax was the predominant cause of
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malaria, accounting for 54% of all malaria cases. Whereas the overall risk of mortality in
patients presenting with P. falciparum fell from 0.53% to less than 0.25% in the posttransition
period, there was no fall in mortality associated with P. vivax, possibly reflecting a higher likeli-
hood of concomitant nonmalarial morbidities in severely ill patients with P. vivax malaria
[34,35]. In the community, the proportion of patients with P. falciparum gametocytes on
blood film examination halved (from 1.4% to 0.7%), whereas the proportion of patients with P.
vivax gametocytes remained unchanged at about 2% (Fig 3).
P. vivax is less amenable than P. falciparum to control by enhanced or scaled-up antimalar-
ial treatment efforts [6,7,36]. Mass drug administration that does not include antirelapse ther-
apy has little effect on P. vivax [3]. There are several biological reasons for this refractoriness.
Firstly, P. vivax gametocytes appear early during the course of an infection and are therefore
more likely than P. falciparum gametocytes, which appear later, to have been transmitted to
mosquitoes prior to antimalarial treatment. Secondly, failure to sterilize the liver of hypno-
zoites can result in multiple subsequent relapses and thus much greater transmission potential
from a single inoculation of P. vivax as compared with P. falciparum. Thirdly, immunity to P.
vivax develops early in endemic regions because of the high force of infection from relapses
[22,37]. This results in a large pool of asymptomatic patients who probably still harbour game-
tocytes and therefore remain infectious to mosquitoes [38,39].
Although DP provides posttreatment prophylaxis against P. vivax recurrence for up to 42
days, it has minimal effect on P. vivax relapses thereafter. At the same time as the change in
blood schizontocidal treatment policy, the recommended dose of primaquine for radical cure
of P. vivax infections was revised from a total dose of 3.5 mg/kg to 7 mg/kg to treat the rela-
tively primaquine-tolerant P. vivax strains in Papua [40]. If safely and effectively delivered,
high-dose primaquine regimens should produce a significant reduction in P. vivax transmis-
sion. However, in Timika, the provision of unsupervised high-dose primaquine combined
with DP has, at best, a modest effect on the likelihood of representation to hospital with vivax
malaria [16]. We postulate that nonadherence to unsupervised primaquine is one of the most
likely explanations for the minimal decline in P. vivax incidence in the region.
Our study has several important strengths. The multifaceted surveillance system incorpo-
rated prospectively collected community and hospital data along with before-and-after cross-
sectional surveys, providing a means of checking the consistency of the findings across various
settings and thus increasing confidence in the internal validity of our results. Data on nonma-
laria presentations to hospital enabled us to control the hospital data for population growth by
presenting the proportional burden of malaria over time. High-quality microscopy services
both at the hospital and in the community clinics are maintained by accredited microscopists,
whose performance is reviewed regularly [22]. Consistent procedures for examination and
reporting of blood films therefore support the validity of longitudinal assessments of Plasmo-
dium species distributions observed in our analysis. Individualized clinical data at RSMM with
linkage to pharmacy and haematology data enabled a very large-scale assessment of the tempo-
ral trends in malaria-related morbidity (in addition to incidence) in the hospital population.
Our study also has some significant limitations. Estimates of the local population were
imprecise because of large transient migrant groups who were excluded from censuses. This
was an issue particularly in the latter years, when the population at risk of malaria may have
been underestimated; thus, our estimates of the reduction in malaria incidence are likely to be
conservative. The estimated change in the proportion of malaria patients detected by the sur-
veillance network was derived from two assessments of treatment-seeking behaviour in 2005
and 2013 [28]. In a sensitivity analysis, assuming no shift in treatment-seeking behaviour, the
estimated reduction in the incidence of falciparum malaria was only 28%, with a 6% rise in the
incidence P. vivax malaria. However, changes in treatment-seeking behaviour should not have
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confounded estimates of the proportion of malaria due to P. vivax or the reduction in hospital-
related morbidity. The surveillance system captured changes in human–mosquito attack rates
and climate variability but did not record concurrent vector-control interventions. Through-
out most of the study period, formal vector-control activities were supported by the mine-sup-
ported PHMC program. These activities remained relatively constant, apart from a large bed
net distribution and IRS program in urban Timika that commenced in 2013, towards the end
of the posttransition period. Changes in vector-control measures were therefore unlikely to
have influenced to a significant extent the reduction in malaria incidence between the pre–pol-
icy change and late transition periods. Finally, in view of the variations in treatment-seeking
behaviour and healthcare provision, an a priori decision was made to compare the malarial
outcomes between the pre-policy and the late transition periods. Although comparison of
dichotomised temporal data can result in loss of power and in type I error, multivariable
regression analyses of unconstrained monthly data confirmed the observed trends and demon-
strated that they were still apparent after controlling for population growth and vector biting.
In summary, in Papua, Indonesia, a change in antimalarial treatment policy from failing
drugs to highly efficacious artemisinin-based treatment for both uncomplicated and severe
malaria was associated with a modest reduction in the overall incidence of malaria but a signif-
icant reduction in malaria-related hospital admissions and mortality. In this area coendemic
for both P. falciparum and P. vivax, there was a marked increase in the proportion of malaria
attributable to P. vivax. Additional scale-up of the existing treatment strategy is likely to result
in further reductions in P. falciparum transmission; however, in order to reduce P. vivax trans-
mission significantly, antirelapse therapy will need to be delivered more effectively. Novel
strategies are being developed to improve primaquine adherence through community educa-
tion campaigns and directly observed supervision of treatment [41]. The availability of point-
of-care testing for G6PD deficiency raises the possibility of introducing short-course high-
daily-dose primaquine regimens and tafenoquine that will facilitate further adherence to a
complete course of treatment [42,43]. In coendemic regions, access to safe and effective radical
cure of malaria for all patients at risk of malaria will be critical for the timely elimination of
malaria.
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